QurAlis Initiates the First Patient Dosing of QRL-201 in P-I for the Treatment of Amyotrophic Lateral Sclerosis
Shots:
- The company dosed the first patient with QRL-201 in the P-I clinical trial (ANQUR) in Canada with an aim to rescue STMN2 expressions in ALS patients through QRL-201
- The P-I clinical trial (ANQUR) evaluates the safety, tolerability & PK of QRL-201 vs PBO in patients with ALS. The primary objective of the study is to determine the safety & tolerability of QRL-201 at multiple doses in patients (n=64) with ALS across Canada, US, UK, Belgium, Netherlands, Italy, Germany & Ireland
- STATHMIN-2 is a protein responsible for neural repairment along with axonal stability & is the most significantly regulated gene by TDP-43. QRL-201 aims to restore STATHMIN-2 expression in ALS patients
Ref: PR Newswire | Image: QurAlis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
